Cardiac Insight has signed a marketing agreement with i.SigNal, DreamTech's digital healthcare specialty brand and organization, based in South Korea. Under this agreement, i.SigNal will use Cardiac Insight's single-use wearable ECG patch and Cardea SOLO ™, a proprietary analysis software system, in the Asia-Pacific (APAC) region, including South Korea, Singapore, India, Japan and Australia. 

Cardea SOLO™, a wire-free ECG recording patch and software analysis system, is an integral part of the world's only comprehensive 7-day outpatient ECG system, enabling rapid automated cardiac analysis and reporting within the clinic.

Cardea SOLO ™ provides doctors with a significant improvement in cardiac arrhythmia detection and diagnostic rates due to its high resolution, medical grade design and longer patient wear time compared to traditional 1- or 2-day Holter ECG monitors.

It also enhances data privacy, security, and cost effectiveness by retaining valuable patient data within the medical institution while maximizing the productivity of hospital and clinic staff per ECG test. The Cardea SOLO ™ system is a stand-alone solution that does not require internet access, cloud computing solutions, or outsourcing to a third party.

Dreamtech CEO Min Kim said: “Cardiac Insight's ECG patch technology, which undermines the market, provides attractive value to the Asia-Pacific market, including South Korea, by bringing productivity gains to healthcare systems. This partnership will help doctors detect and diagnose serious cardiac arrhythmias that can cause disability, such as atrial fibrillation, stroke, heart failure, and death, and improve the way they are treated. With our resources and a rich history of market innovation, development and outstanding branding, we help provide healthcare solutions to doctors and their patients in the Asia-Pacific region that are among the most exciting and impactful in the world. It's a thing and we're proud. "

Dreamtech's i.Sig Nal obtained a Cardea SOLO medical device license from the Korea Food and Drug Administration at the end of 2020, and is proceeding with approval and sales activities in other Asia-Pacific markets.